Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Australian companies race to raise capital, share placements top $6 billion

04/16/2020 | 07:11pm EST
Outbreak of the coronavirus disease (COVID-19) in Sydney, Australia

Australian companies have raised more than A$10 billion ($6.29 billion), the second highest on record, from selling new shares this year as they rush to raise funds as a buffer against the economic downturn triggered by the new coronavirus.

It makes Australia the most active capital market in the Asian region so far this year excluding China.

Refinitiv data on Australian equity capital market activity since the start of 2020 shows 152 deals worth A$10.26 billion, surpassed only by the figure of $11.9 billion raised during the same period five years ago.

"We have seen extremely active debt markets globally, particularly in the U.S., where the Fed has injected massive liquidity via a broad spectrum of measures," Goldman Sachs Australia's head of equity capital markets, Sarah Rennie, said.

"Australia doesn't have the equivalent depth of debt markets and so I think Australian corporates have turned more quickly to equity investors for support."

Australia's economy, supported by its natural resources sector, has proved resilient to previous downturns, but analysts predict it is on course for its first recession in three decades as entire sectors of the economy are shut to stop the spread of the coronavirus.

Bankers say they expect demand for the equity deals from investors will be sustained in Australia as companies seek funding, even as global financial markets remain volatile.

The Australian regulator, ASIC and the Australian Securities Exchange (ASX) announced in mid-March companies would be temporarily able to issue placements worth 25% of their shares on issue, up from a previous cap of no more than 15%.

RBC Capital Markets Head of Equities Karen Jorritsma said the capital raisings had been well supported by investors.

"Equities still look relatively favourable from an asset allocation point of view and I think the appetite for deals will continue in the near term, but corporates are better to be first than last to avoid being caught up in deal fatigue," she said.

The Refinitiv data showed the most active markets outside Australia for companies raising cash included India, which has raised $5.9 billion, while Japan has raised $3 billion.

The Australian capital raisings have been led by insurer QBE, which raised A$1.2 billion this week, Oil Search, which tapped the market for A$1.16 billion and Cochlear, with A$880 million, stock exchange filings from those companies showed.

"I wouldn't expect the activity levels of the past few weeks to be maintained over a long period, but I do expect that there will be some more of these raisings to come, especially in the lead up to debt covenant testing," Herbert Smith Freehills partner Philippa Stone said.

By Scott Murdoch


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASX LIMITED -2.29% 70.84 End-of-day quote.-1.61%
BYD COMPANY LIMITED -1.29% 245.8 End-of-day quote.20.96%
COCHLEAR LIMITED 0.71% 190.8 End-of-day quote.0.95%
LONDON BRENT OIL -2.91% 54.8 Delayed Quote.9.17%
OIL SEARCH LIMITED 0.23% 4.41 End-of-day quote.18.87%
QBE INSURANCE GROUP LIMITED -1.83% 8.57 End-of-day quote.0.47%
SEEK LIMITED -0.73% 27.1 End-of-day quote.-5.01%
THE GOLDMAN SACHS GROUP, INC. -2.23% 301.01 Delayed Quote.14.14%
THE LEAD CO., INC. 1.69% 842 End-of-day quote.0.24%
Latest news "Companies"
04:45pFacebook to ban ads promoting weapon accessories, protective gear in U.S.
RE
04:23pCanada's Couche-Tard to explore partnership opportunities with Carrefour, after takeover plan fails
RE
04:17pSERVIER : announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy
BU
03:37pSHAREHOLDER ACTION ALERT : The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Decision Diagnostics Corp. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
BU
03:13pINVESTOR REMINDER : Kessler Topaz Meltzer & Check, LLC Reminds Investors of Splunk Inc. of Fast Approaching Deadline
GL
03:03pCOVID-19 : Provinces work on revised plans as Pfizer-BioNTech shipments to slow down
AQ
03:01pQUANTUMSCAPE : ROSEN, LEADING GLOBAL INVESTOR COUNSEL, Reminds QuantumScape Corporation Investors of Important March 8 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - QS
PR
02:55pALERT : Halper Sadeh LLP Reminds Investors of Its Ongoing Merger Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, CGIX, UROV
GL
02:44pCARREFOUR : Alimentations Couche-Tard, Carrefour consider partnerships after takeover talks end
AQ
02:41pGoldman Sachs nudges U.S. growth forecast higher on Biden stimulus plan
RE
Latest news "Companies"